From Hitachi Medical Systems America, Inc.;
because of its dependability, the MRP-7000™ remains popular more than a decade after the first U.S. system was shipped. This system maintains a high resale value, what has made it one of the most sought-after scanners on the used MRI equipment market.

MS-325 is the formerly code name of gadofosveset trisodium (new trade name Vasovist). MS-325 belongs to a new class of blood pool agents for magnetic resonance angiography (MRA) to diagnose vascular disease. Gadofosveset trisodium has ten times the signal-enhancing power of existing contrast agents as well as prolonged retention in the blood. This enables the rapid acquisition of high resolution MRA's using standard MRI machines.
Gadofosveset trisodium, which is gadolinium-based, stays in the blood stream as a result of transient binding to albumin. Albumin binding offers an additional benefit beyond localization in the blood pool. The contrast agent begins to spin much more slowly, at the rate albumin spins, causing a relaxivity gain that produces a substantially brighter signal than would be possible with freely circulating gadolinium. MS-325 is an intravascular contrast agent intended for use in MRI as an aid in diagnosing aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease (PVD) or abdominal aortic aneurysm (AAA).
Currently clinical trials completed for peripheral vascular disease and coronary artery disease. Additional trials are also being conducted to evaluate MS-325 as an aid in diagnosing breast cancer and suggested that it might be feasible to combine the use of MS-325, injected during peak stress, with delayed high-resolution imaging to identify myocardial perfusion defects.
Vasovist (MS-325) would compete with the contrast agents Ferumoxytol (Code 7228) from AMAG Pharmaceuticals, Inc. and NC100150 Injection from Nycomed Amersham, but their further development is uncertain.
Partners in development: EPIX Pharmaceuticals, Inc., Mallinckrodt Inc., and Bayer Schering Pharma AG. Bayer Schering Pharma has the worldwide marketing rights for the product.
Formerly known under the Mallinckrodt trademark name, AngioMARK®.

See also Classifications, Characteristics, etc.

From Philips Medical Systems;
the Panorama 0.23 T, providing a new design optimized for patient comfort, faster reconstruction time than before (300 images/second) and new gradient specifications. Philips' Panorama 0.23 T I/T supports MR-guided interventions, resulting in minimally invasive procedures, more targeted surgery, reduced recovery time and shorter hospital stays. Optional OptoGuide functionality enables real-time needle tracking. Philips' Panorama 0.23 TPanorama 0.2 R/T is the first and only open MRI system to enable radiation therapy planning using MR data sets. The Panorama also features the new and consistent Philips User Interface, an essential element of the Vequion clinical IT family of products and services.

From Philips Medical Systems;
Panorama 0.6 T is the Philips Mid-Field Open MRI system. It is the most open MR scanner in the market, optimized for patient comfort and faster reconstruction time.

From Philips Medical Systems;
this active shielded member of the Panorama product line combines the advantages of one 1.0 T system's with the possibilities of an open MRI system. The open design helps ease anxiety for claustrophobic patients and increased patient comfort whereby the field strength provides spectacular image quality and fast patient throughput.